PMZ 1620Alternative Names: PMZ1620
Latest Information Update: 22 Dec 2016
At a glance
- Originator Pharmazz
- Mechanism of Action Angiogenesis inducing agents; Neurogenesis stimulants; Neuron modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cerebrovascular disorders
- Clinical Phase Unknown Solid tumours
- Preclinical Neurodegenerative disorders